Stock comparison
ResMed
Teva Pharmaceutical Industries Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
TEVA
Teva Pharmaceutical Industries Limited
Market cap
$39.67B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | TEVA | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 46D | RMD |
| Benjamin Graham | 75B | 60D | RMD |
| Philip Fisher | 75B | 59C | RMD |
| Peter Lynch | 58C | 53C | RMD |
| Joel Greenblatt | 47D | 49D | TEVA |
| Charlie Munger | 69B | 50D | RMD |
| Terry Smith | 73B | 41D | RMD |
Side-by-side metrics
| Metric | RMD | TEVA |
|---|---|---|
| Market cap | $30.18B | $39.67B |
| P/E (TTM) | 19.6x | 25.4x |
| EV/EBIT | 17.1x | 24.8x |
| ROIC (TTM) | 19.63% | 11.49% |
| Gross margin | 61.69% | 51.98% |
| Net margin | 27.44% | 9.03% |
| Revenue CAGR 5y | 12.64% | 2.1% |
| EPS CAGR 5y | 30.73% | 34.13% |
| Debt / Equity | 0.1x | 2.1x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Debt / Equity0.1xvs 2.1x+94%
- Revenue CAGR 5y12.64%vs 2.1%+83%
- Net margin27.44%vs 9.03%+67%
TEVA leads on
- Market cap$39.67Bvs $30.18B+24%
- EPS CAGR 5y34.13%vs 30.73%+10%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.